Title : An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.

Pub. Date : 2009 Jun

PMID : 19192258






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVES: The overall objective of this study was to estimate the costs and outcomes associated with treatment with valsartan for post-myocardial infarction (post-MI) patients with left ventricular systolic dysfunction, heart failure, or both, who are not suitable for treatment with angiotensin-converting enzyme (ACE) inhibitors, compared to placebo. Valsartan angiotensin I converting enzyme Homo sapiens
2 OBJECTIVES: The overall objective of this study was to estimate the costs and outcomes associated with treatment with valsartan for post-myocardial infarction (post-MI) patients with left ventricular systolic dysfunction, heart failure, or both, who are not suitable for treatment with angiotensin-converting enzyme (ACE) inhibitors, compared to placebo. Valsartan angiotensin I converting enzyme Homo sapiens
3 CONCLUSIONS: For patients who are not suitable for treatment with ACE inhibitors, valsartan is a viable and cost-effective treatment for their management after an MI. Valsartan angiotensin I converting enzyme Homo sapiens